Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Accumulated Depreciation & Amortization (2018 - 2023)

Historic Accumulated Depreciation & Amortization for Marker Therapeutics (MRKR) over the last 6 years, with Q1 2023 value amounting to $6.1 million.

  • Marker Therapeutics' Accumulated Depreciation & Amortization rose 8371.46% to $6.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $6.1 million, marking a year-over-year increase of 8371.46%. This contributed to the annual value of $5.3 million for FY2022, which is 9246.68% up from last year.
  • As of Q1 2023, Marker Therapeutics' Accumulated Depreciation & Amortization stood at $6.1 million, which was up 8371.46% from $5.3 million recorded in Q4 2022.
  • Marker Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $6.1 million during Q1 2023, with a 5-year trough of $10514.0 in Q1 2019.
  • For the 5-year period, Marker Therapeutics' Accumulated Depreciation & Amortization averaged around $2.0 million, with its median value being $1.4 million (2021).
  • As far as peak fluctuations go, Marker Therapeutics' Accumulated Depreciation & Amortization soared by 3166867.47% in 2019, and later soared by 8371.46% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Accumulated Depreciation & Amortization stood at $105472.0 in 2019, then soared by 460.59% to $591264.0 in 2020, then skyrocketed by 363.44% to $2.7 million in 2021, then surged by 92.47% to $5.3 million in 2022, then grew by 15.51% to $6.1 million in 2023.
  • Its last three reported values are $6.1 million in Q1 2023, $5.3 million for Q4 2022, and $4.7 million during Q3 2022.